EXPAVON INFUSION is used to treat low blood volume (hypovolemia). Hypovolemia is a condition in which the body has low blood volume, usually due to excessive fluid loss from bleeding, dehydration, or severe burns. If untreated, it can lead to low blood pressure, poor organ oxygen delivery, and potential shock. The treatment involves fluid replacement with crystalloids or colloids to restore circulation.

EXPAVON INFUSION contains Hydroxyethyl starch. It draws water into the bloodstream, increasing plasma volume and improving circulation. In cases of low blood volume (hypovolemia), it helps maintain blood pressure and organ perfusion. Its effects are temporary and depend on dose, molecular weight, and infusion rate.

The dose and duration of treatment with EXPAVON INFUSION may vary depending on your medical condition. Common side effects include itching, reduced plasma proteins, decreased hematocrit, and increased serum amylase. Most of these side effects gradually resolve on their own. However, please consult the doctor if they persist or worsen.

Inform your doctor if you are pregnant or breastfeeding before receiving EXPAVON INFUSION . It is unknown whether EXPAVON INFUSION interacts with alcohol or not. However, as a precautionary measure, it is best to avoid alcohol to prevent potential risks. Inform your doctor if you have heart, kidney, or liver problems or any pre-existing health conditions and about all the medicines you are taking to minimize the risk of potential side effects.

EXPAVON INFUSION belongs to the group of medications called plasma volume expanders and is used to treat hypovolemia. It helps replace lost blood volume, improving blood flow and pressure. It supports vital organ function and stability during operations or injury, reducing the risk of shock and fluid loss.

Inform your doctor if you have cardiac insufficiency, severe kidney dysfunction, or electrolyte imbalances, as the fluid overload risk is higher. Fluid status and infusion rates should be carefully monitored. In severe dehydration, a crystalloid should be given first. Patients undergoing open-heart surgery should be closely observed, as EXPAVON INFUSION may increase bleeding risk. Coagulation status should be monitored, and use should be discontinued if coagulopathy occurs. High doses of EXPAVON INFUSION may affect blood clotting, haematocrit, and plasma proteins. Liver function should be checked due to potential amylase elevation. If you experience hypersensitivity reactions, including anaphylaxis, stop using EXPAVON INFUSION immediately. Avoid using EXPAVON INFUSION in patients with pre-existing renal dysfunction and discontinue immediately if renal injury occurs. Monitor kidney function for at least 90 days, as kidney replacement therapy may be required. Prolonged use of EXPAVON INFUSION may cause severe and persistent itching. Its use in children is limited and should only be under strict medical supervision, with individualized dosage for newborns and premature infants. Inform your doctor if you are pregnant, breastfeeding, or taking other medications to prevent potential interactions.